Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LIXT Lixte Biotechnology	$3.59 -7.9%	$2.89	$0.64 ▼ $5.14	$17.79M	0.43	159,309 shs	100,968 shs
NXTC NextCure	$5.10 -1.1%	$5.44	$2.69 ▼ $19.80	$13.78M	1.25	319,515 shs	8,007 shs
TXMD TherapeuticsMD	$1.17 +1.7%	$1.15	$0.70 ▼ $2.44	$13.31M	0.42	23,564 shs	32,873 shs
VRAX Virax Biolabs Group	$0.77 +4.4%	$0.87	$0.72 ▼ $9.00	$3.20M	1.66	149,713 shs	23,250 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LIXT Lixte Biotechnology	-7.95%	-25.67%	-3.49%	+160.14%	+70.95%
NXTC NextCure	-1.07%	+4.62%	+5.71%	-3.06%	-72.43%
TXMD TherapeuticsMD	+1.71%	+9.85%	+1.73%	-22.01%	-27.78%
VRAX Virax Biolabs Group	+3.08%	-2.04%	-16.40%	-28.70%	-55.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LIXT Lixte Biotechnology	0.1552 of 5 stars	0.0	2.0	0.0	1.7	0.8	0.0
NXTC NextCure	4.3198 of 5 stars	3.3	3.0	4.3	2.4	1.7	1.3
TXMD TherapeuticsMD	0.4953 of 5 stars	0.0	3.0	0.0	2.3	0.0	0.6
VRAX Virax Biolabs Group	3.4366 of 5 stars	3.5	5.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LIXT Lixte Biotechnology	0.00	N/A	N/A	N/A
NXTC NextCure	2.67	Moderate Buy	$25.50	400.49% Upside
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A
VRAX Virax Biolabs Group	3.00	Buy	$3.00	289.61% Upside

Current Analyst Ratings Breakdown

Latest VRAX, LIXT, NXTC, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	$0.14 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$11.82 per share	N/A
TXMD TherapeuticsMD	$1.76M	7.69	N/A	N/A	$2.36 per share	0.50
VRAX Virax Biolabs Group	$10K	334.18	N/A	N/A	$1.26 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LIXT Lixte Biotechnology	-$3.59M	-$1.29	N/A	∞	N/A	N/A	N/A	-222.90%	N/A
NXTC NextCure	-$55.65M	-$25.82	N/A	N/A	N/A	N/A	-106.62%	-85.20%	N/A
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	N/A
VRAX Virax Biolabs Group	-$6.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/1/2025 (Estimated)

Latest VRAX, LIXT, NXTC, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million
8/7/2025	Q2 2025	LIXT Lixte Biotechnology	N/A	-$0.29	N/A	-$0.29	N/A	N/A
8/7/2025	Q2 2025	NXTC NextCure	-$4.62	-$11.29	-$6.67	-$11.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LIXT Lixte Biotechnology	N/A	1.84	1.84
NXTC NextCure	N/A	3.71	3.71
TXMD TherapeuticsMD	N/A	2.89	2.64
VRAX Virax Biolabs Group	N/A	7.27	7.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LIXT Lixte Biotechnology	5.10%
NXTC NextCure	42.65%
TXMD TherapeuticsMD	30.74%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
LIXT Lixte Biotechnology	14.80%
NXTC NextCure	17.90%
TXMD TherapeuticsMD	2.30%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LIXT Lixte Biotechnology	4	4.56 million	2.29 million	Not Optionable
NXTC NextCure	90	2.68 million	2.20 million	Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable
VRAX Virax Biolabs Group	5	4.34 million	2.38 million	Not Optionable

VRAX, LIXT, NXTC, and TXMD Headlines

Recent News About These Companies

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

July 29, 2025 | prnewswire.com

Virax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...

July 22, 2025 | finance.yahoo.com

Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 20, 2025 | finanznachrichten.de

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 18, 2025 | prnewswire.com

HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation

March 31, 2025 | msn.com

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

March 31, 2025 | benzinga.com

Virax Biolabs Launches Clinical Study on T Cell Dysfunction

March 18, 2025 | msn.com

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

March 18, 2025 | prnewswire.com

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

March 13, 2025 | prnewswire.com

Virax Biolabs to Present at 19th World Immune Regulation Meeting

March 5, 2025 | prnewswire.com

Virax Biolabs Aligns with US Health Department on Vaccine Transparency

February 25, 2025 | tipranks.com

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

February 25, 2025 | prnewswire.com

Cosmos Health expands distribution of Avian Influenza kits

January 23, 2025 | msn.com

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

January 23, 2025 | accessnewswire.comA

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

January 13, 2025 | accesswire.comA

Virax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?

December 19, 2024 | bovnews.comB

Virax Biolabs Announces Strategic Goals and Developments for 2025

December 18, 2024 | markets.businessinsider.com

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

December 17, 2024 | prnewswire.com

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

December 10, 2024 | prnewswire.com

Virax Biolabs Sees Asset Growth Amid Financial Loss

November 22, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, LIXT, NXTC, and TXMD Company Descriptions

Lixte Biotechnology NASDAQ:LIXT

$3.59 -0.31 (-7.95%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.61 +0.02 (+0.56%)

As of 08/15/2025 05:16 PM Eastern

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

NextCure NASDAQ:NXTC

$5.10 -0.06 (-1.07%)

Closing price 08/15/2025 03:47 PM Eastern

Extended Trading

$4.95 -0.14 (-2.77%)

As of 08/15/2025 07:56 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

TherapeuticsMD NASDAQ:TXMD

$1.17 +0.02 (+1.71%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$1.14 -0.03 (-2.56%)

As of 08/15/2025 07:44 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Virax Biolabs Group NASDAQ:VRAX

$0.77 +0.03 (+4.41%)

Closing price 08/15/2025 03:54 PM Eastern

Extended Trading

$0.77 0.00 (0.00%)

As of 08/15/2025 07:38 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time